TC Biopharm (Holdings) Past Earnings Performance
Past criteria checks 0/6
TC Biopharm (Holdings) has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been declining at an average rate of 18.2% per year.
Key information
11.2%
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -18.2% |
| Return on equity | -795.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How TC Biopharm (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -9 | 7 | 7 |
| 31 Dec 23 | 0 | -6 | 7 | 7 |
| 30 Sep 23 | 1 | -4 | 7 | 7 |
| 30 Jun 23 | 3 | -2 | 7 | 8 |
| 31 Mar 23 | 3 | -2 | 8 | 7 |
| 31 Dec 22 | 4 | -1 | 9 | 7 |
| 30 Sep 22 | 3 | -4 | 8 | 7 |
| 30 Jun 22 | 2 | -10 | 7 | 7 |
| 31 Mar 22 | 2 | -12 | 5 | 7 |
| 31 Dec 21 | 2 | -14 | 3 | 6 |
| 30 Sep 21 | 2 | -11 | 2 | 6 |
| 30 Jun 21 | 2 | -5 | 2 | 6 |
| 31 Mar 21 | 2 | -5 | 2 | 6 |
| 31 Dec 20 | 2 | -5 | 2 | 7 |
| 31 Dec 19 | 3 | -6 | 3 | 9 |
Quality Earnings: T0U0 is currently unprofitable.
Growing Profit Margin: T0U0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: T0U0 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare T0U0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: T0U0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-16%).
Return on Equity
High ROE: T0U0 has a negative Return on Equity (-795.37%), as it is currently unprofitable.